Bausch Health Cos (BHC) Projected to Announce Earnings on Wednesday

Bausch Health Cos (NYSE:BHC - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Bausch Health Cos to post earnings of $1.25 per share and revenue of $2.72 billion for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 5:00 PM ET.

Bausch Health Cos (NYSE:BHC - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. The business had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. On average, analysts expect Bausch Health Cos to post $4.35 EPS for the current fiscal year and $4.02 EPS for the next fiscal year.

Bausch Health Cos Stock Up 1.3%

Shares of Bausch Health Cos stock opened at $6.41 on Wednesday. Bausch Health Cos has a 12 month low of $4.33 and a 12 month high of $8.00. The business has a fifty day simple moving average of $6.17 and a 200 day simple moving average of $5.61. The stock has a market cap of $2.40 billion, a PE ratio of -2.16 and a beta of 0.37.

Insider Activity

In related news, insider Aimee Lenar sold 36,827 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the sale, the insider owned 334,853 shares in the company, valued at $2,354,016.59. This represents a 9.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on BHC shares. Jefferies Financial Group raised Bausch Health Cos to a "hold" rating in a research note on Wednesday, July 22nd. Zacks Research upgraded Bausch Health Cos from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 21st. Weiss Ratings upgraded Bausch Health Cos from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday, July 31st. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $9.00 price target on shares of Bausch Health Cos in a research report on Thursday, October 8th. Finally, Wall Street Zen raised shares of Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $8.00.

About Bausch Health Cos

Bausch Health Companies Inc NYSE: BHC is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.